Acotec Scientific Holdings Limited 2025 Annual Report: Key Insights for Investors

Executive Summary

Acotec Scientific Holdings Limited (“Acotec” or the “Company”) has released its 2025 Annual Report, providing a comprehensive overview of its financial performance, capital management, investment plans, risk factors, and governance. The following article provides investors with a detailed summary of key points, price-sensitive developments, and material information relevant to share value.

Financial Highlights and Performance

• Revenue Growth: The Group’s total revenue increased to RMB 644.6 million in 2025 (from RMB 534.0 million in 2024), reflecting robust growth in its core medical device business. Revenue was primarily generated from the sale of core products and other medical devices to distributors.
• Profitability: Profit attributable to ordinary equity shareholders rose sharply to RMB 119.2 million in 2025, more than doubling from RMB 52.3 million in 2024. This significant increase underscores operational efficiency and the successful execution of business strategies.
• Other Income: Total other income for 2025 was RMB 52.7 million, including RMB 24.8 million in government grants and RMB 25.7 million in interest income. Government grants were mainly for technology innovation and rewarding contributions to the local economy.
• Other Net Gains/Losses: The Group reported net other gains of RMB 0.2 million in 2025, reversing a net loss of RMB 4.8 million in 2024. This includes foreign exchange losses, disposal losses, and gains from financial assets.
• Earnings Per Share (EPS): Basic EPS was RMB 0.40 in 2025, up from RMB 0.17 in 2024. Diluted EPS for 2025 was RMB 0.39. No dilutive potential ordinary shares existed in 2024.

Capital Management and Financial Position

• Capital Expenditure: In 2025, the Group’s capital expenditure was approximately RMB 81.2 million, mainly for plant, equipment, and intangible assets.
• Distributable Reserves: As at December 31, 2025, the Company had distributable reserves of RMB 1,387.4 million, up from RMB 1,371.9 million in 2024.
• Bank Borrowings: The Group maintained adequate bank credit lines and had no charges on assets or significant contingent liabilities.
• Share Capital: The Company’s share capital remained unchanged at 313,389,171 shares, with no new shares issued or treasury shares held.

Use of IPO Proceeds

The Company received net proceeds of RMB 1,294 million from its IPO. As of December 31, 2025, RMB 1,238.3 million had been utilized, with RMB 55.6 million unutilized. Major uses included:

• Development and commercialization of core products (fully utilized)
• Development of other 24 products and expansion of production capacity (fully utilized)
• In-house R&D, collaborations, and mergers (RMB 55.6 million yet to be used, expected by 2027)
• Working capital and loan repayment (fully utilized)

Dividend Policy and Shareholder Returns

• No final dividend is recommended for FY2025, consistent with prior years. The Board intends to retain earnings for business growth and expansion, with periodic reviews of this policy.
• Legal and regulatory restrictions in the PRC may limit the ability to pay dividends, depending on distributable profits and subsidiary distributions.

Investments, Acquisitions & M&A Activity

• No significant investments, material acquisitions, or disposals were reported in 2025.
• The Group continues to seek growth through self-development, mergers, and acquisitions, with funding from internal resources and bank loans.
• Unlisted units in investment funds and unlisted equity securities are held as financial assets, with their fair values disclosed and subject to periodic revaluation.

Risk Management and Internal Controls

• The Board has overall responsibility for risk management and internal control, with systems deemed effective and adequate following annual review.
• Key risks include: dependency on successful commercialization of product candidates, uncertainty in clinical product development, potential delays or failure in clinical trials, and risk of non-acceptance by physicians and hospitals.
• Foreign currency risk is material, especially with exposure to USD. A 5% change in USD exchange rate could impact profit after tax by approximately RMB 28.1 million.

Corporate Governance and Compliance

• The Company maintained high standards of corporate governance, with full compliance with the CG Code except for noted deviations.
• All directors confirmed compliance with the Model Code for securities transactions, and appropriate insurance coverage for directors and officers was maintained.
• No material litigation, legal proceedings, or breaches of laws and regulations were reported during the year.
• The Company has no dividend policy in the near term and no plans for major changes to constitutional documents.

Share Incentive Schemes

• The Share Award Scheme allows up to 10% of issued shares for awards. Selected participants’ contributions are considered for awards, and all grants comply with regulatory requirements.
• Awarded shares are subject to vesting conditions, and participants have no rights to dividends or voting on unvested shares.
• Equity-settled share-based payments of RMB 9.3 million were recorded in 2025.

Employee and Human Resource Highlights

• The Group employed 653 staff as of December 31, 2025, mainly in China.
• Competitive salaries, project incentives, and stock options are provided to attract and retain talent. Compliance with labor laws is maintained, with training for management and staff.

Environmental, Social, and Regulatory Compliance

• The Company actively pursues sustainability initiatives and complies with environmental laws and regulations. No material non-compliance was reported.

Outlook and Strategic Initiatives

• Acotec continues to focus on expanding its product development pipeline, market expansion in China and globally, and exploring mergers and acquisitions for further growth.
• Management is confident that available bank credit lines are sufficient to support planned investments and operations.

Important Shareholder Information and Price-Sensitive Matters

• Strong profit growth and revenue increase may be positive catalysts for share price.
• No dividend payout and continued earnings retention could impact income-focused investors.
• Significant unutilized IPO proceeds earmarked for R&D and M&A could lead to future business expansion or strategic investments.
• Exposure to foreign currency risk may impact future earnings, especially with USD fluctuations.
• No major legal, regulatory, or compliance issues were identified, supporting stability and risk mitigation.
• Continued expansion and product innovation remain at the core of Acotec’s growth strategy, with potential for future price-moving news as new products reach commercialization or as M&A deals are executed.

Conclusion

Acotec Scientific Holdings Limited has delivered robust financial results for 2025, driven by strong revenue and profit growth. While the absence of a dividend may disappoint some investors, the Group’s focus on R&D, product pipeline expansion, and prudent capital management positions it for sustainable long-term growth. Investors should monitor developments related to new product launches, M&A activity, and utilization of remaining IPO funds, as these could serve as catalysts for future share price movements.

Disclaimer: This article is a summary and interpretation of the 2025 Annual Report of Acotec Scientific Holdings Limited, intended for informational purposes only. It does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making investment decisions. The author is not responsible for any loss arising from reliance on the information provided herein.

View ACOTEC-B Historical chart here